Data reported from several studies have shown vaccine efficacy to be between 80% and 99% following single-dose vaccination and 98% or greater with 2 doses of the vaccine.
Evans thinks Virxsys has made this less likely by limiting the vaccine virus to a single cycle of infection.
Evans认为VIRxSYS通过限制病毒单次感染而将这种可能减小。
3
Current WHO estimates suggest that the vaccine storage requirements would at least double if only single-dose presentations were used (WHO vaccine volume calculator, March 2011).